InsiderTrades

Form 4 for LGND LIGAND PHARMACEUTICALS INC

Accepted 2021-08-05 00:00:00 ET · period of report 2021-08-04 · accession 0000886163-21-000121 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2021-08-05 2021-08-04 LGND FOEHR MATTHEW W Pres, COO M - OptEx $29.23 +9,982 165.5K +6% +$291.7K
D 2021-08-05 2021-08-04 LGND FOEHR MATTHEW W Pres, COO S - Sale+OE $109.67 -8,840 164.4K -5% -$969.5K
DM 2021-08-05 2021-08-04 LGND FOEHR MATTHEW W Pres, COO M - OptEx $0.00 -9,982 25.9K -28% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-08-04 M A 8,840 $21.92 173,195 D — —
2 Common Common Stock 2021-08-04 S D 8,840 $109.67 164,355 D — — (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.06 to $111.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3 Common Common Stock 2021-08-04 M A 1,142 $85.79 165,497 D — —
4 Derivative Employee Stock Option (right to buy) 2021-08-04 M D 8,840 $0.00 11,160 D $21.92 · — to 2023-02-15 8,840 Common Stock (F2) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
5 Derivative Employee Stock Option (right to buy) 2021-08-04 M D 1,142 $0.00 25,938 D $85.79 · — to 2026-02-11 1,142 Common Stock (F3) Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/11/16.